Is there a future for ovulation induction in the current era of assisted reproduction?

  • Van Santbrink E
  • Fauser B
  • 10


    Mendeley users who have this article in their library.
  • 28


    Citations of this article.


The clinical use of medical induction of ovulation in normogonadotrophic anovulatory women (WHO II), including polycystic ovary syndrome, is increasingly questioned. However, we believe that this treatment modality still represents a highly effective means of fertility treatment in women with low pregnancy chances without intervention. A conventional treatment algorithm involving clomiphene citrate (CC) followed by FSH induction of ovulation may result in a 71% cumulative singleton live birth rate. In attempts to improve treatment outcome further and reduce complication rates, new compounds such as insulin-sensitizing agents or aromatase inhibitors are currently used increasingly. Approaches such as patient selection for different treatment modalities on the basis of initial screening characteristics and alternative protocols for FSH ovulation induction may also be proposed to render treatment algorithms more patient tailored and therefore improve overall outcomes. More research is needed in this area, rather than referring these patients to assisted reproduction prematurely. This may lead to a more individually tailored approach for ovulation induction in a given patient, resulting in a further improvement of the balance between chances for success versus complications.

Author-supplied keywords

  • Anovulation
  • FSH
  • Ovulation induction
  • Prediction model
  • Step-down

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • E. J.P. Van Santbrink

  • B. C.J.M. Fauser

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free